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resulting incremental cost per QALY of 7721 demonstrated
that maintenance therapy with rituximab when compared to
observation was cost-effective. The cost per QALY was very
robust when subject to extensive one-way and probabilistic sen-
sitivity analysis. Probabilistic sensitivity analyses indicated that
the likelihood of the ICER being below 10,000 was 90%.
CONCLUSION: From the perspective of UK NHS, maintenance
rituximab when compared to observation alone for the treatment
of relapsed/refractory follicular NHL patients responding to
induction therapy is a highly cost-effective treatment.
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OBJECTIVES: In Hungary the standard therapy in the adjuvant
treatment of stage III colon cancer is the DeGramont-protocol, a
combination of 5-ﬂuorouracil and leucovorin. In the MOSAIC
trial the addition of oxaliplatin (FOLFOX4) improved the efﬁcacy
of the standard therapy in this patient group. The aim of our study
was to evaluate the cost-effectiveness of FOLFOX4 compared to
standard therapy in Hungary.METHODS: The cost-utility analy-
sis of the FOLFOX4 therapy was based on theMOSAIC trial. The
efﬁcacy data of the MOSAIC trial was extrapolated for lifetime,
while utilities values were incorporated from published sources.
Age and gender speciﬁc general mortality rates and utilities were
derived from epidemiology data of the Hungarian population and
published utilities based on the EQ-5D questionnaire. The analy-
sis was accomplished from payer perspective. Thus, only direct
medical costs were taken into account. Resource use was based on
Hungarian treatment patterns and unit costs. Costs and outcomes
were discounted at 5%. Cost-effectiveness was measured in terms
of incremental cost per quality-adjusted life year saved (QALY),
incremental cost per disease-free years (DFY) and incremental
cost per life-years saved (LYS). One-way sensitivity analysis
was employed. RESULTS: Compared to DeGramont therapy,
FOLFOX4 resulted in an additional 0.455 QALY, 0.531 LYS,
0.958 DFY andHUF 1,310,064 (5,240€) per patient. The cost for
one QALY was HUF 2,880,342 (11,521€), while for one DFS and
LYS was HUF 1,367,712 (5,471€) and HUF 2,468,660 (9,875€),
respectively. The results were most sensitive to discount rate,
general population data and the cost of chemotherapy.CONCLU-
SION: Based on the possible thresholds in Hungary, and the
€20,000/QALY quoted in countries of the EU zone, FOLFOX4 is
a cost-effective strategy inHungary for the postoperative adjuvant
treatment of patients with stage III colon cancer compared to the
DeGramont protocol.
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OBJECTIVES: The aim of the study was to analyze the cost-
effectiveness of sunitinib malate, a novel cancer treatment, as a
second-line therapy for metastatic renal cell carcinoma (mRCC)
after ﬁrst-line cytokine treatment compared with current Finnish
treatment practice. Cytokine therapy is currently the standard
ﬁrst line treatment for mRCC. Until recently, treatments with
proven efﬁcacy after the failure of ﬁrst line cytokine therapy have
not been available. METHODS: Information for analyses was
gathered from clinical trials, the literature and patient records
from two Finnish university hospitals. Clinical experts treating
mRCC-patients in Finland provided the information on current
practices for the sunitinib treatment. A comprehensive probabi-
listic decision-analytic model was developed using WinBUGS
software to estimate the cost-effectiveness and expected value
of perfect information (EVPI) of sunitinib malate. An EVPI
approach was used to estimate the expected costs of decision
uncertainty. A societal perspective was assumed in all analyses to
avoid suboptimal decisions. RESULTS: The Kaplan-Meier sur-
vival estimates after cytokine failure for local patients (n = 39)
were 3.8 months (95% CI, 2.16–5.51) and 1.4 months (95% CI,
0.7–2.17) for overall and progression-free survival, respectively.
When compared to the current Finnish treatment practice, suni-
tinib prolonged life expectancy by 1 year and resulted in a
progression-free time of 6.3 months and in 0.7 QALYs gained.
Over a ﬁve-year time period, an incremental cost-effectiveness
ratio (ICER) of 42,877€ per QALY was obtained. Sunitinib was
estimated to have an 88% probability of being cost-effective at
the willingness-to-pay level of 45,000€/QALY. The population
EVPI for the decision between sunitinib-treatment and current
Finnish treatment practice was 607,000€ at a willingness-to-pay
level of 42,500€. CONCLUSION: Sunitinib malate results in
improved survival and is potentially cost-effective as a second-
line treatment of mRCC compared to the current clinical practice
used in Finnish hospitals.
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OBJECTIVES: Maintenance therapy with rituximab has shown
signiﬁcant improvements in overall survival and progression-free
survival (PFS) when compared with observation in patients with
relapsed/refractory follicular lymphoma (van Oers et al., 2006).
The primary objective of this analysis was to estimate the incre-
mental cost-efectiveness ratio (ICER) of rituximab maintenance
therapy versus observation alone, based on data from the
EORTC 20981 study. METHODS: Rituximab maintenance
therapy (375 mg/m2 every 3 months) was evaluated using a
Markov model. All patients entered in the model following
response to CHOP chemotherapy +/- rituximab as induction
therapy. PFS and Overall Survival (OS) following rituximab
maintenance were extrapolated from 2-year Kaplan-Meier
curves from the study data using a parametric approach. Cox-
Snell and deviance residuals were analysed. Quality-of-life utility
values were derived from a study of 165 patients using the
EQ-5D questionnaire. Direct annual medical costs including
adverse events, drug acquisition, administration and preparation
were estimated accordingly to a Delphi panel with Brazilian
haematologists. Costs were reported in 2007 Brazilian Reais.
Both costs and outcomes were discounted at 3.5% rate according
to NICE/UK recommendation. In order to assess uncertainty,
probabilistic sensitivity analyses were also performed. A lifetime
horizon and a payer perspective in Brazil were adopted.
RESULTS: Rituximab maintenance resulted in a gain of 1.79
QALYs (5.96 vs. 4.17) at an incremental cost of R$57,595 The
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